Scientific publications

Helper-dependent adenovirus achieve more efficient and persistent liver transgene expression in non-human primates under immunosuppression

Unzu C(1), Melero I(2) [SP], Hervás-Stubbs S(3), Sampedro A(1), Mancheño U(1), Morales-Kastresana A(1), Serrano-Mendioroz I(1), de Salamanca RE(4), Benito A(5) [SP], Fontanellas A(6).
(1) Immunotherapy and Hepatology Area, Centre for Applied Medical Research (CIMA), University of Navarra, Spain.
(2) [1] Immunotherapy and Hepatology Area, Centre for Applied Medical Research (CIMA), University of Navarra, Spain [2] Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain [3] Department of Oncology, Clínica Universitaria de Navarra, University of Navarra, Pamplona, Spain.
(3) [1] Immunotherapy and Hepatology Area, Centre for Applied Medical Research (CIMA), University of Navarra, Spain [2] Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
(4) Research Center, Hospital Universitario 12 de Octubre, University Complutense of Madrid, Spain.
(5) [1] Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain [2] Department of Radiology, Clínica Universitaria de Navarra, University of Navarra, Pamplona, Spain.
(6) [1] Immunotherapy and Hepatology Area, Centre for Applied Medical Research (CIMA), University of Navarra, Spain [2] Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain [3] CIBERehd, University Clinic Navarra. Instituto de Salud Carlos III. Pamplona, Spain.

Magazine: Gene Therapy

Date: Jun 30, 2015

Medical Oncology Radiology [SP]

Abstract

Helper-dependent adenoviral (HDA) vectors constitute excellent gene-therapy tools for metabolic liver diseases. We have previously shown that an HDA vector encoding human porphobilinogen deaminase (PBGD) corrects acute intermittent porphyria mice.

Now, six non-human primates were injected in the left hepatic lobe with the PBGD-encoding HDA vector to study levels and persistence of transgene expression. Intrahepatic administration of 5 × 1012 viral particles/kg (1010 infective units/kg) of HDA only resulted in transient (≈14 weeks) transgene-expression in one out of three individuals.

In contrast, a more prolonged 90-day immunosuppressive regimen (tacrolimus, mycophenolate, rituximab and steroids) extended meaningful transgene expression for over 76 weeks in two out of two cases. Transgene-expression under immunosuppression reached maximum levels 6 weeks after HDA administration and gradually declined reaching a stable plateau within the therapeutic range for acute porphyria. The non-injected liver lobes also expressed the transgene because of vector circulation. Immunosuppression controlled anti-capsid T-cell responses and decreased the induction of neutralizing antibodies. Re-administration of HDA-hPBGD at week +78 achieved therapeutically meaningful transgene-expression only in those animals receiving immunosuppression again at the time of this second vector exposure.

Overall, immunity against adenoviral capsids poses serious hurdles for long-term HDA-mediated liver transduction, which can be partially circumvented by pharmacological immunosuppression.Gene Therapy accepted article preview online, 30 June 2015. doi:10.1038/gt.2015.64.

CITATION  Gene Ther. 2015 Jun 30. doi: 10.1038/gt.2015.64.

you maybe interested

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra